Effect of Dexamethasone on treatment of COVID-19

Phase 2

Recruiting

Conditions: COVID-19 disease.
COVID-19
U07.2, U07

Registration Number: IRCT20201015049030N1

Lead Sponsor: Tehran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 200

Inclusion Criteria

Outpatients with Covid 19 confirmed by positive PCR test for SARS-CoV-2 or confirmed by abnormal CT scan finding (bilateral, sub pleural, peripheral ground glass opacities),
With blood oxygen saturation between 90-95%
Patients with severe respiratory symptoms such as cough, shortness of breath and severe shortness of breath or CRP above 20 or after three days of standard treatment worsened symptoms of the disease, including exacerbated fevers, aggravated weakness or aggravated shortness of breath based on the physician's clinical judgment

Exclusion Criteria

Patients with a history of underlying disease such as diabetes, malignancies, renal and heart failure, uncontrolled hypertension, and taking immunosuppressive drugs and corticosteroids
Patients with other active infections
Pregnant or lactating women

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
O2 saturation. Timepoint: Before, one and two weeks after dexamethasone treatment. Method of measurement: Pulse Oximeter.;Mortality rate. Timepoint: Before and after dexamethasone treatment. Method of measurement: Observation.;Need for an oxygen therapy. Timepoint: Before and after dexamethasone treatment. Method of measurement: Clinical.;Constitutional. Timepoint: Before, one and two weeks after dexamethasone treatment. Method of measurement: Clinical.;Needs of hospitalization. Timepoint: Before and after treatment. Method of measurement: Observation.

Secondary Outcome Measures

Name	Time	Method
CRP laboratory test. Timepoint: Before, one and two weeks after dexamethasone treatment. Method of measurement: Para-clinical.;CBC laboratory test. Timepoint: Before, one and two weeks after dexamethasone treatment. Method of measurement: Para-clinical.